bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025 [Yahoo! Finance]
bioAffinity Technologies, Inc. (BIAF)
Company Research
Source: Yahoo! Finance
company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced sales of its CyPath ® Lung diagnostic test for lung cancer reached a new high in the third quarter of 2025, representing a 95% increase over the previous quarter. The increase reflects growing adoption by Veterans' hospitals and market expansion in the mid-Atlantic region. In the first nine months of 2025, sales of CyPath ® Lung rose 97% over the same period in 2024. "The continued acceleration in CyPath ® Lung adoption underscores the growing physician confidence in our test to detect lung cancer at its earliest, most treatable stages," said Maria Zannes, President and CEO of bioAffinity Technologies. "Physicians are equally impressed by CyPath ® Lung's ability to save patients from unnecessary invasive procedures when the nodule is benign." "Our strong quarter-over-quarter growth demonstrates that CyPath ® Lung is gaining traction in the marketplace, and we are encouraged by the te
Show less
Read more
Impact Snapshot
Event Time:
BIAF
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BIAF alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BIAF alerts
High impacting bioAffinity Technologies, Inc. news events
Weekly update
A roundup of the hottest topics
BIAF
News
- bioAffinity Technologies’ Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer RoundtableBusiness Wire
- bioAffinity Technologies Reports Third Quarter 2025 Financial ResultsBusiness Wire
- bioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test VolumeBusiness Wire
- bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung DiseasesBusiness Wire
- bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025Business Wire
BIAF
Sec Filings
- 12/3/25 - Form 8-K
- 11/14/25 - Form 10-Q
- 11/14/25 - Form 8-K
- BIAF's page on the SEC website